Just cause yours is a dud dont be jealous of others. Maybe I will chase minnow and let her know what a real man is like.
MRK showing some strength this morning. I see YHOO has a conservative target of around $52 for MRK,fine with me. GLTA
More revenue from existing drugs
"Merck (MRK) recently announced that the U.S. Food and Drug Administration (:FDA) has approved its site at Durham, N.C. for the manufacture of bulk varicella for use in Merck’s chickenpox and shingles vaccines.
Merck intends to get the site approved in future for the production of bulk and finished product for other childhood and shingles vaccines as well. Earlier in 2010, the Durham site had gained approval for the production of finished chickenpox vaccines.
With the latest approval, Merck will be able to boost its vaccine supply and meet the growing demand for its shingles vaccine, Zostavax. Zostavax sales have been increasing with Merck reporting first half 2013 sales of $309 million, up 37.9% from the year-ago period. Zostavax is a key growth driver for Merck. According to the company, a little more than 20% of the targeted U.S. population (age ≥ 60 years) has been vaccinated – this means that there is still a major part of the targeted population that needs vaccination thereby representing huge opportunity for growth.
Demand should increase further with the UK recommending Zostavax for the routine vaccination of individuals aged 70 (and 79 years catch-up cohort) for the prevention of shingles and shingles-related post-herpetic neuralgia from Sep 1, 2013.
Meanwhile, Merck has started launching Zostavax in some Asian markets like Korea and expects to launch in additional markets next year.
Merck’s other varicella-containing vaccine, Varivax, should also benefit from the increased supply. Previously, Merck’s varicella-containing vaccines were being produced at its West Point, Pa., facility.
We note that Merck has been working on expanding its vaccines manufacturing capabilities over the last several years during which the company invested more than $1 billion on the same. In addition to modernizing and expanding vaccine operations at its West Point and Elkton, Va. facilities, Merck has also set up a new facility in Carlow, I
This Low Float Rocket will hit $6++ before FDA decision on October 17 ...PSDV will move into double digits easily with FDA approval for Blockbuster Candidate Iluven .There is NO FDA approved drugs for DME (Diabetic Macular Edema) .
Upon US approval of Iluvien, pSivida would be entitled to receive a $25 million milestone payment from Alimera and 20 percent of net profits, as defined, on sales of the drug by Alimera.
DME is a potentially blinding disease that affects over one million people in the United States. Currently there are no FDA approved drugs for the treatment of DME.The U.S. market for DME is $1.5 billion to $4 billion.
Pfizer is third largest Shareholder of PSDV holding 1.9 M Shares . PSDV is very close to profitability .
Market Cap: $88 M
Cash: $24 M
Shares Out: 26.8 M ( 10.4 M shares held by Insiders & Institutions)
“We are very pleased that the FDA has accepted Alimera Sciences’ recently resubmitted New Drug Application for ILUVIEN® for chronic Diabetic Macular Edema (DME) and has set a PDUFA target date of October 17, 2013." Upon US approval of Iluvien, pSivida would be entitled to receive a $25 million milestone payment from Alimera and 20 percent of net profits, as defined, on sales of the drug by Alimera.
The injectable, sustained release micro-insert ILUVIEN® for the treatment of chronic DME considered insufficiently responsive to available therapies, licensed to Alimera Sciences, Inc., has received marketing authorization in Austria, France, Germany, Portugal, Spain and the U.K. and is awaiting authorization in Italy.
lol your right this is a shorters dream. MRK will never hold $48+ load up on the monthly $47.5 PUTS and just wait to collect.
I smell capitulation & fear shorty,it went through $48 like a knife thorough hot butter you're right LOL!!
"BMO Capital increased its EPS estimates on shares of Merck (MRK) through 2014 as the company’s product pipeline remains solid. In the report, BMO maintained its market perform rating and set a $50 price target. Shares of Merck were higher by 0.9% on the news."